Sort   by:  
 Page size 
TranscriptomicsGlobal analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with Eralpha
Background: The ZNF217 gene, encoding a C2H2 zinc finger protein, is located at 20q13 and found amplified and overexpressed in greater than 20% of breast tumors. Current studies indicate ZNF217 drives tumorigenesis, yet the regulatory mechanisms of ZNF217 are largely unknown. Because ZNF217 associat...
ORGANISM(S): Homo sapiens 
2014-06-15 | E-GEOD-58326 | biostudies-arrayexpress
TranscriptomicsIdentification of genes directly regulated by the oncogene ZNF217 using ChIP-chip assays (Promoter Arrays)
It has been proposed that ZNF217, which is amplified at 20q13 in various tumors, plays a key role during neoplastic transformation. ZNF217 has been purified in complexes that contain repressor proteins such as CtBP2, suggesting that it acts as a transcriptional repressor. However, the function of ZN...
ORGANISM(S): Homo sapiens 
2010-06-12 | E-GEOD-6625 | biostudies-arrayexpress
ProteomicsFrequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma (Global Proteome and PPI)
Recent exome-wide studies discovered frequent somatic mutations in the epigenetic modifier ZNF217 in primary mediastinal B cell lymphoma (PMBCL) and related disorders. As functional consequences of ZNF217 alterations remain unknown, we comprehensively evaluated their impact in PMBCL. Targeted sequen...
ORGANISM(S): Homo sapiens (Human) 
2024-01-26 | PXD034337 | Pride
Znf217 Pmbcl Non-hodgkin lymphoma Genetics Precision medicine Mutation Copy-number aberration 
ProteomicsFrequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma (Phospho-Proteome)
Recent exome-wide studies discovered frequent somatic mutations in the epigenetic modifier ZNF217 in primary mediastinal B cell lymphoma (PMBCL) and related disorders. As functional consequences of ZNF217 alterations remain unknown, we comprehensively evaluated their impact in PMBCL. Targeted sequen...
ORGANISM(S): Homo sapiens (Human) 
2024-01-26 | PXD040928 | Pride
Znf217 Phosphoproteome Pmbcl Non-hodgkin lymphoma Genetics Mutation 
GenomicsZNF217 promotes ovarian cancer progression by impacting multiple pivotal steps in the metastatic process
ZNF217 promotes ovarian cancer progression
PRJEB101637 | ENA
GenomicsRNA-seq of wild-type and ZNF217-knockout KOPN-8 cells
RNA-seq of wild-type and ZNF217-knockout KOPN-8 cells
PRJNA1136576 | ENA
GenomicsEffect of ZNF217 gene knockdown on gene expression in MHCC97H cells
Effect of ZNF217 gene knockdown on gene expression in MHCC97H cells
PRJNA1379459 | ENA
GenomicsCUT&RUN sequencing of wild-type and ZNF217-knockdown KOPN-8 cells
CUT&RUN sequencing of wild-type and ZNF217-knockdown KOPN-8 cells
PRJNA1136575 | ENA
ProteomicsIdentification of ZNF217 interactors in MCF7 breast cancer cell line
Identification of TRPS1 interactors in MCF7 breast cancer cell line.
ORGANISM(S): Homo sapiens (Human) 
2018-07-17 | PXD010312 | Pride
Znf217 Breast Rime 
TranscriptomicsThe transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression
The transcription factor ZNF217 is a candidate oncogene in the amplicon on chromosome 20q13 that occurs in 20-30% of primary human breast cancers and that correlates with poor prognosis. We show Znf217 overexpression drives aberrant differentiation and signaling events, promotes increased self-renew...
ORGANISM(S): Mus musculus 
2012-05-17 | E-GEOD-24727 | biostudies-arrayexpress
Sort   by:  
 Page size